Working... Menu
Trial record 49 of 282 for:    Best Disease

Clopidogrel Response Evaluation and AnTi-Platelet InterVEntion in High Thrombotic Risk PCI Patients (CREATIVE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01779401
Recruitment Status : Completed
First Posted : January 30, 2013
Last Update Posted : July 19, 2017
Beijing Municipal Health Bureau
Haemonetics Corporation
Zhejiang Otsuka Pharmaceutical Co., Ltd.
Information provided by (Responsible Party):
Yi-Da Tang, Chinese Academy of Medical Sciences, Fuwai Hospital